Navigation Links
Research needed to learn which DCIS patients may be candidates for less invasive therapy
Date:9/25/2009

Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is not well understood. Because most women diagnosed with DCIS are treated, it is difficult to determine the comparative benefits of different treatment strategies versus active surveillance, meaning systematic followup. An independent panel convened by the NIH urged the scientific community to identify appropriate biomarkers and other prognostic factors to better predict the risk of developing breast cancer.

"Instead of treating all women diagnosed with DCIS, we need to determine which individuals are likely to develop invasive breast cancer and which will not," said Dr. Carmen Allegra, panel chair and Chief of Hematology and Oncology at the University of Florida. "If we could accurately predict this, we might save some women from undergoing unnecessary invasive treatments while achieving the same positive outcomes."

DCIS is a condition in which a spectrum of abnormal cells are found in the breast duct and have not spread outside the duct to other tissues in the breast. Since the advent of widespread screening mammography in the early to mid 1980's, rates of DCIS have increased sharply. It is estimated that more than one million U.S. women will be living with a prior diagnosis of DCIS by 2020.

Despite the connotations associated with the term carcinoma, DCIS is associated with ten-year survival rates close to 100% when treated with currently available therapies. These include breast-conserving surgery (local excision, with or without radiation), removal of the breast (mastectomy), and/or tamoxifen. It is important to stress that each of these treatment options has physical and emotional impacts to patients and should be weighed accordingly. The panel recognized that there are relatively few reliable data on the comparative effectiveness
'/>"/>

Contact: Lisa Ahramjian
AhramjianL@od.nih.gov
301-496-4999
NIH/National Institutes of Health, Office of Disease Prevention
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Research network based at University of Toronto gets $5 million boost to speed up cancer detection
2. AFOSRs basic research may lead to revolutionary new devices
3. New research network at McMaster aims to build a better eye
4. WPI receives $1.3 million in federal awards for ongoing research in the life sciences
5. Stem cell applications and research highlight NJITs first Research Cafe
6. NIH announces 115 awards to encourage high-risk research and innovation
7. New genetic research indicates Jewish priesthood has multiple lineages
8. Prestigious $4.9 million NIH grant awarded to Case Western Reserve for colon cancer research
9. UNC scientists garner new NIH awards for high risk, transformative research
10. Researchers identify new brain pathway for regulating weight and bone mass
11. McGill garners 19 Canada Research Chairs and more than $17 million in funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
(Date:7/7/2015)... Research and Markets ... the "Capacitive Fingerprint Sensors Patent Landscape" ... date, fingerprint sensing technology is the most reliable ... well developed. This patent landscape focuses on fingerprint ... domain of capacitive fingerprint sensors is closely linked ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... are consuming at least double the recommended amount of salt ... at the University of Gothenburg and Sahlgrenska University Hospital. "It,s ... and something needs to be done about it. We can ... salt intake later on in life, in the form of ...
... discovered a chemical compound in a sponge off Palau, ... shown anticancer, antibacterial, and antifungal pharmaceutical promise. But that ... This compound, called Palau,amine, is so chemically complex ... laboratory became the most hotly pursued synthetic chemistry goal ...
... birds can help pinpoint likely carrier species and geographic ... to enter North America, according to new U.S. Geological ... pathogenic avian influenza H5N1 (HPAI H5N1) virus in Eurasia ... transported among continents by migratory birds has resulted in ...
Cached Biology News:Scripps Research team wins global race to achieve landmark synthesis of perplexing natural product 2Scripps Research team wins global race to achieve landmark synthesis of perplexing natural product 3Scripps Research team wins global race to achieve landmark synthesis of perplexing natural product 4New research findings can improve avian flu surveillance programs 2
(Date:8/3/2015)... MARIETTA, Ga. , Aug. 3, 2015  MiMedx ... medicine company utilizing human amniotic tissue and patent-protected processes ... the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic ... will present at the 35 th Annual Canaccord|Genuity ...  Parker H. "Pete" Petit, Chairman and CEO, William ...
(Date:8/3/2015)... Delaware , August 3, 2015 ... in the commercialization of its Bio-electrical Signal Therapy device ... noninvasive treatment of hard to heal chronic wounds, today ... agreement with Chemipal, an Israeli distributor specializing in medical ... device. Chemipal is a 70 years old, ...
(Date:7/31/2015)... VEGAS , July 31, 2015 ... seek resources that help them drive positive health ... a vital source of patient care in their ... annual tradeshow and conference, AmerisourceBergen announced a ... its Pharmacy Services Administration Organization and help independent ...
(Date:7/30/2015)... 2015 AACC welcomed thousands of medical ... Annual Meeting & Clinical Lab Expo in ... meeting showcased revolutionary advancements in clinical testing technology ... providers to diagnose patients quickly and accurately and ... As of Wednesday, July 29, more ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4
... , , , High-quality ... efficient gene silencing in eukaryotic cell culture by targeting complementary , ... , gene silencing in functional genomics studies. Now, ... service that includes a range of modifications , ...
... , , Stefanie Schrer, Werner Wittke,* and , ... Germany , , * Leica ... , Laser microdissection (LMD) provides a powerful , ... This eliminates the problems of cell-type heterogeneity within tissue samples , ...
... , , The proven activated dendrimer for transfection , ... Features and benefits , , ... range of cell lines , Transfection in the presence of serum ... ") , High transient and stable transfection efficiencies , ...
Cached Biology Technology:Custom and library siRNA for efficient gene silencing 2Custom and library siRNA for efficient gene silencing 3Custom and library siRNA for efficient gene silencing 4Custom and library siRNA for efficient gene silencing 5Laser microdissection and nucleic acid purification - a Leica - QIAGEN , cooperation 2Laser microdissection and nucleic acid purification - a Leica - QIAGEN , cooperation 3Laser microdissection and nucleic acid purification - a Leica - QIAGEN , cooperation 4SuperFect Transfection Reagent 2SuperFect Transfection Reagent 3